Intract Pharma

Intract Pharma logo

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.

Contact Intract Pharma via their website

News archive

22/04/2021   Intract Pharma and NIBEC Enter into an Agreement to Develop Ulcerative Colitis Treatment...more
01/04/2021   Intract Pharma Enters into Research Collaboration with Ferring Pharmaceuticals...more

20/08/2020   Intract Pharma Limited and Celltrion Group announce collaboration...more
26/05/2020   Intract Pharma and N&S Pharmacy Investment announce partnership...more
05/05/2020   Intract Pharma and Elasmogen Ltd announce collaboration...more

24/10/2019   Intract’s Soteria® and Phloral® Highlighted Among Revolutionary Delivery Approaches...more
07/05/2019   Carus Animal Health and Intract Pharma Announce Drug Delivery partnership...more
05/04/2019   Intract Pharma and Neopharma Japan Enter Collaborate to Develop GI Novel Treatment...more
27/03/2019   Intract Pharma announces market launch of Phloral® colon-targeting product...more

28/11/2018   Intract Pharma nominated for Genesis 2018 BioNewsRound Award...more
22/03/2018   Intract Pharma joins the BioPartner programme...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code